Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.

Detalles Bibliográficos
Autores principales: Haj Najeeb, Bilal, Schmidt-Erfurth, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275938/
https://www.ncbi.nlm.nih.gov/pubmed/36175488
http://dx.doi.org/10.1038/s41433-022-02249-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275938/
https://www.ncbi.nlm.nih.gov/pubmed/36175488
http://dx.doi.org/10.1038/s41433-022-02249-2

Ejemplares similares